Artemisinin Combination - Global Market Outlook (2017-2026)

Artemisinin Combination - Global Market Outlook (2017-2026)

  • Published: November 2018
  • ID: SMRC17751

According to Stratistics MRC, the Global Artemisinin Combination Therapy (ACT) market is accounted for $338.80 billion in 2017 and is expected to reach $830.98 billion by 2026 growing at a CAGR of 10.5% during the forecast period. Rising pipeline for new anti-malarial drugs, growing demand for artemisinin combination therapy (ACT) and increasing government initiatives are few factors propelling for the growth of the market. However, limited number of manufacturers globally acts as a hindrance for the market growth.

Based on type, Artesunate–Mefloquine is a lucrative market for Artemisinin Combination Therapy (ACT) due to its quick spread of resistance, mediated mainly by a raise in copy number and expression of the P. falciparum multi-drug resistance (MDR) gene. This improves bioavailability and reduces vomiting. There is no formulation of mefloquine for children. Regardless of earlier restrictions there is no cause to withhold mefloquine for young children. Limited information recommends that mefloquine is perhaps secure in pregnancy.

By geography, Middle East and Africa held the largest market share in the artemisinin combination therapy owing to have large number of production base of artemisinin herbs and growing demand in malaria endemic countries which are contributing to the expansion of the market in MEA. Though African countries, where the occurrence of malaria is high, so they have amplified malaria control strategies, efficient treatment and control, but it still presents a huge logistical difficulty. As numerous at-risk people survive in extreme poverty in isolated areas, WHO and other organizations are working on completely eradicating it in Africa and thus, over the coming years, the adoption rate of ACT is further expected to boost.

Some of the key players profiled in the Artemisinin Combination Therapy (ACT) market include KPC Pharmaceuticals, Inc., Shanghai Fosun Pharmaceutical Industrial Development Company Limited, Sanofi, Desano Holdings Ltd., Calyx Chemicals and Pharmaceuticals Limited, Mylan N.V., Novartis AG, Denk Pharma GmbH & Co. KG, Hovid Berhad, Ipca Laboratories Limited, Cipla Limited and Aspen Pharmacare Holdings Limited. 

Types Covered:
• Artesunate–Sulfadoxine–Pyrimethamine
• Artesunate–Mefloquine
• Artesunate–Pyronaridine
• Artemether–Lumefantrine
• Artesunate–Amodiaquine
• Dihydroartemisinin–Piperaquine
    
Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan       
    • China       
    • India       
    • Australia 
    • New Zealand     
    • South Korea      
    • Rest of Asia Pacific   
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary           
              

2 Preface            
 2.1 Abstract           
 2.2 Stake Holders          
 2.3 Research Scope          
 2.4 Research Methodology         
  2.4.1 Data Mining         
  2.4.2 Data Analysis         
  2.4.3 Data Validation         
  2.4.4 Research Approach         
 2.5 Research Sources          
  2.5.1 Primary Research Sources        
  2.5.2 Secondary Research Sources        
  2.5.3 Assumptions         
             
3 Market Trend Analysis          
 3.1 Introduction          
 3.2 Drivers           
 3.3 Restraints          
 3.4 Opportunities          
 3.5 Threats           
 3.6 Emerging Markets          
 3.7 Futuristic Market Scenario         
             
4 Porters Five Force Analysis          
 4.1 Bargaining power of suppliers         
 4.2 Bargaining power of buyers         
 4.3 Threat of substitutes         
 4.4 Threat of new entrants         
 4.5 Competitive rivalry          
             
5 Global Artemisinin Combination Therapy (ACT) Market, By Type  
     
 5.1 Introduction          
 5.2 Artesunate–Sulfadoxine–Pyrimethamine       
 5.3 Artesunate–Mefloquine         
 5.4 Artesunate–Pyronaridine         
 5.5 Artemether–Lumefantrine         
 5.6 Artesunate–Amodiaquine         
 5.7 Dihydroartemisinin–Piperaquine        
             
6 Global Artemisinin Combination Therapy (ACT) Market, By Geography      
 6.1 Introduction          
 6.2 North America          
  6.2.1 US          
  6.2.2 Canada          
  6.2.3 Mexico          
 6.3 Europe           
  6.3.1 Germany          
  6.3.2 UK          
  6.3.3 Italy          
  6.3.4 France          
  6.3.5 Spain          
  6.3.6 Rest of Europe         
 6.4 Asia Pacific          
  6.4.1 Japan          
  6.4.2 China          
  6.4.3 India          
  6.4.4 Australia          
  6.4.5 New Zealand         
  6.4.6 South Korea         
  6.4.7 Rest of Asia Pacific         
 6.5 South America          
  6.5.1 Argentina         
  6.5.2 Brazil          
  6.5.3 Chile           
  6.5.4 Rest of South America        
 6.6 Middle East & Africa         
  6.6.1 Saudi Arabia         
  6.6.2 UAE          
  6.6.3 Qatar          
  6.6.4 South Africa         
  6.6.5 Rest of Middle East & Africa        
             
7 Key Developments           
 7.1 Agreements, Partnerships, Collaborations and Joint Ventures      
 7.2 Acquisitions & Mergers         
 7.3 New Product Launch         
 7.4 Expansions          
 7.5 Other Key Strategies         
             
8 Company Profiling           
 8.1 KPC Pharmaceuticals, Inc.         
 8.2 Shanghai Fosun Pharmaceutical Industrial Development Company Limited    
 8.3 Sanofi           
 8.4 Desano Holdings Ltd.         
 8.5 Calyx Chemicals and Pharmaceuticals Limited        
 8.6 Mylan N.V.          
 8.7 Novartis AG          
 8.8 Denk Pharma GmbH & Co. KG         
 8.9 Hovid Berhad          
 8.10 Ipca Laboratories Limited         
 8.11 Cipla Limited          
 8.12 Aspen Pharmacare Holdings Limited        


List of Tables            
1 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Region (2016-2026) (US $MN)    
2 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)   
3 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
4 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN)  
5 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN) 
6 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN) 
7 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN) 
8 Global Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN) 
9 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)   
10 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)   
11 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
12 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN) 
13 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN) 
14 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN) 
15 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN) 
16 North America Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)
17 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)    
18 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)   
19 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
20 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN) 
21 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN) 
22 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN) 
23 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN) 
24 Europe Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN) 
25 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)    
26 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)   
27 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
28 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN) 
29 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN) 
30 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN) 
31 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN) 
32 Asia Pacific Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)
33 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)   
34 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)   
35 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
36 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN) 
37 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN) 
38 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN) 
39 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN) 
40 South America Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)
41 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Country (2016-2026) (US $MN)   
42 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Type (2016-2026) (US $MN)  
43 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Sulfadoxine–Pyrimethamine (2016-2026) (US $MN)
44 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Mefloquine (2016-2026) (US $MN)
45 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Pyronaridine (2016-2026) (US $MN)
46 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artemether–Lumefantrine (2016-2026) (US $MN)
47 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Artesunate–Amodiaquine (2016-2026) (US $MN)
48 Middle East & Africa Artemisinin Combination Therapy (ACT) Market Outlook, By Dihydroartemisinin–Piperaquine (2016-2026) (US $MN)

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Site License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials